



(12) Translation of
European patent specification

(11) NO/EP 3458479 B1

NORWAY

(19) NO
(51) Int Cl.
C07K 16/28 (2006.01)
A61K 31/00 (2006.01)
A61K 39/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2021.04.19
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.11.04
(86)	European Application Nr.	17732657.6
(86)	European Filing Date	2017.06.07
(87)	The European Application's Publication Date	2019.03.27
(30)	Priority	2016.06.08, US, 201662347476 P 2016.07.25, US, 201662366511 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(73)	Proprietor	AbbVie Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA
(72)	Inventor	BENATUIL, Lorenzo, 33 Mohawk Drive, NorthboroughMA 101532, USA BRUNCKO, Milan, 31231 Prairie Ridge Road, Green OaksIL 60048, USA CHAO, Debra, 4846 Balthazar Terrace, FremontCA 94555, USA IZERADJENE, Kamel, 1443 Clavey Lane, GurneeIL 60031, USA JUDD, Andrew, S., 138 Mainsail Drive, GrayslakeIL 60030, USA PHILLIPS, Andrew, C., 519 Garfield Avenue, LibertyvilleIL 60048, USA SOUERS, Andrew, J., 156 Blueberry Road, LibertyvilleIL 60048, USA THAKUR, Archana, 8378 Moller Ranch Drive, PleasantonCA 94588, USA
(74)	Agent or Attorney	CURO AS, Vestre Rosten 81, 7075 TILLER, Norge

(54)	Title	ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
(56)	References Cited:	US-A1- 2012 294 796 WO-A1-2016/094505

LEONG STEVEN R ET AL: "An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer", MOLECULAR PHARMACEUTICS, ACS PUBLICATIONS, USA, vol. 12, no. 6, 1 June 2015 (2015-06-01), pages 1717-1729, XP008178294, ISSN: 1543-8392, DOI: 10.1021/MP5007745 [retrieved on 2015-04-23]

HANS-PETER GERBER ET AL: "Antibody drug-conjugates targeting the tumor vasculature", MABS, vol. 1, no. 3, 1 May 2009 (2009-05-01), pages 247-253, XP055186637, ISSN: 1942-0862, DOI: 10.4161/mabs.1.3.8515

MAHIUDDIN AHMED ET AL: "Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 290, no. 50, 11 December 2015 (2015-12-11), pages 30018-30029, XP055396132, US ISSN: 0021-9258, DOI: 10.1074/jbc.M115.679852

D. LOO ET AL: "Development of an Fc-Enhanced Anti-B7-H3 Monoclonal Antibody with Potent Antitumor Activity", CLINICAL CANCER RESEARCH, vol. 18, no. 14, 15 July 2012 (2012-07-15), pages 3834-3845, XP055092714, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-12-0715

Deryk Loo ET AL: "Abstract 1201: Anti-B7-H3 antibody-drug conjugates as potential therapeutics for solid cancer", Poster presented at AACR annual meeting, April 16-20, 2016, New Orleans, USA Cancer Research, 20 April 2016 (2016-04-20), pages 1201-1201, XP055396737, DOI: 10.1158/1538-7445.AM2016-1201 Retrieved from the Internet:
 URL:http://files.shareholder.com/downloads/AMDA-278VRP/0x0x886237/E3742E18-80FE-4E9D-BA3B-FDA5E0B5EA32/MacroGenics_AACR_2016_-_Anti-B7-H3_Antibody-drug_Conjugates.pdf [retrieved on 2017-08-07] & "MacroGenics Presents Data from Five Preclinical Programs at AACR Annual Meeting 2016", MacroGenics Press release, 19 April 2016 (2016-04-19), XP055396285, Retrieved from the Internet:
 URL:<http://ir.macrogenics.com/common/download/download.cfm?companyid=AMDA-278VRP&fileid=886563&filekey=03D3915B-D68D-4906-B67E-BB61941CF359&filename=965754.pdf>

E. PICARDA ET AL: "Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy", CLINICAL CANCER RESEARCH, vol. 22, no. 14, 20 May 2016 (2016-05-20), pages 3425-3431, XP055396638, US ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-15-2428

S KOENIG: "targeting B7-H3 in cancer", MEDICOGRAPHIA, vol. 36, no. 3, 1 January 2014 (2014-01-01), pages 285-292, XP055400455,

ASHER MULLARD: "Pioneering apoptosis-targeted cancer drug poised for FDA approval", NATURE REVIEWS. DRUG DISCOVERY, vol. 15, no. 3, 2 March 2016 (2016-03-02), pages 147-149, XP055422099, GB ISSN: 1474-1776, DOI: 10.1038/nrd.2016.23


C. PETERS ET AL: "Antibody-drug conjugates as novel anti-cancer chemotherapeutics", BIOSCIENCE REPORTS, vol. 35, no. 4, 12 June 2015 (2015-06-12), pages e00225-e00225, XP055301629, US ISSN: 0144-8463, DOI: 10.1042/BSR20150089

AKIKO NAGASE-ZEMBUTSU ET AL: "Development of DS-5573a: A novel afucosylated mAb directed at B7-H3 with potent antitumor activity", CANCER SCIENCE, vol. 107, no. 5, 26 April 2016 (2016-04-26), pages 674-681, XP055396124, JP ISSN: 1347-9032, DOI: 10.1111/cas.12915

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Anti-humant B7H3 (hB7-H3)-antistoff-medikament-konjugat (ADC) som omfatter den følgende strukturen:



5 hvori m er 2 og Ab er et anti-hB7-H3 antistoff, hvori antistoffet Ab omfatter

et CDR3-domene av en tung som omfatter aminosyresekvensen vist i SEQ ID NO: 35, et CDR2-domene av en tung kjede som omfatter aminosyresekvensen vist i SEQ ID NO: 34, og et CDR1-domene av en tung kjede som omfatter aminosyresekvensen vist i SEQ ID NO: 33; og et CDR3-domene av en lett kjede som omfatter aminosyresekvensen vist i SEQ ID NO: 39, et CDR2-domene av en lett kjede som omfatter aminosyresekvensen vist i SEQ ID NO: 38, og et CDR1-domene av en lett kjede som omfatter aminosyresekvensen vist i SEQ ID NO: 37.

2. Antistoff-medikament-konjugat ifølge krav 1, hvori antistoffet omfatter en variabel region av en tung kjede som omfatter SEQ ID NO: 147 og en variabel region av en lett kjede som omfatter SEQ ID NO: 144.

15 3. Antistoff-medikament-konjugat ifølge krav 1, hvori antistoffet omfatter har en tung kjede som omfatter SEQ ID NO: 168 og en lett kjede som omfatter SEQ ID NO: 169.